The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer

Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemother...

Full description

Saved in:
Bibliographic Details
Published in:Breathe (Lausanne, Switzerland) Switzerland), 2024-10, Vol.20 (3), p.240044
Main Authors: Mayenga, Marie, Pedroso, Ana Rita, Ferreira, Marion, Gille, Thomas, Pereira Catarata, Maria Joana, Duchemann, Boris
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.
ISSN:1810-6838
2073-4735
DOI:10.1183/20734735.0044-2024